PLRX250117C25000
- 0.05
- 0.000.00%
Pliant Therapeutics Newsroom
Leerink Partners Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $33
Positive Developments in Pliant Therapeutics' IPF Research Bolster Buy Rating
A Quick Look at Today's Ratings for Pliant Therapeutics(PLRX.US), With a Forecast Between $32 to $45
Pliant Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
Pliant Therapeutics Analyst Ratings
RBC Capital Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $45
Needham Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $38
TD Cowen Maintains Pliant Therapeutics(PLRX.US) With Buy Rating
Pliant Therapeutics (PLRX) Receives a Buy From TD Cowen
Piper Sandler Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $40
Pliant Therapeutics (PLRX) Gets a Buy From Piper Sandler
Pliant Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
Pliant Therapeutics Analyst Ratings
H.C. Wainwright Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $38
Buy Rating Affirmed for Pliant Therapeutics on Strong Bexotegrast Clinical Data and Broad Therapeutic Potential
Leerink Partners Initiates Pliant Therapeutics(PLRX.US) With Buy Rating, Announces Target Price $33
Oppenheimer Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $45
CCORF Maintains Pliant Therapeutics(PLRX.US) With Buy Rating, Maintains Target Price $43
Pliant Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Pliant Therapeutics, Raises Price Target to $38